JOSEPH ALCALAY, M.D.; MICHAEL DAVID, M.D.; MICHAL LOTEM, M.D.; MIRIAM SANDBANK, M.D.
To the editor: In 1984, Bunn and associates (1) reported that high-dose recombinant leukocyte A interferon was highly effective in the treatment of advanced refractory cutaneous T-cell lymphoma. However, it was difficult to assess survival. The same group, by getting more clinical experience with the drug, stated that interferon alfa-2a is a treatment of choice for patients with advanced cutaneous T-cell lymphomas refractory to chemotherapy and other standard forms of therapy (2). Based on these reports, we recently treated a patient who had Sézary syndrome refractory to previous forms of therapy with high-dose recombinant interferon alfa-2a.
A 55-year-old woman has
JOSEPH ALCALAY, MICHAEL DAVID, MICHAL LOTEM, MIRIAM SANDBANK. Interferon and T-Cell Lymphoma. Ann Intern Med. 1987;107:428. doi: 10.7326/0003-4819-107-2-428_1
Download citation file:
Published: Ann Intern Med. 1987;107(3):428.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use